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Evaluation of cariprazine in the treatment of bipolar I and II 
depression: a randomized, double-blind, placebo-controlled, 
phase 2 trial
Lakshmi N. Yathama, Eduard Vietab and Willie Earleyc  
This double-blind placebo-controlled, fixed/flexible-
dose phase 2 trial assessed the efficacy, safety, and 
tolerability of cariprazine vs. placebo for depressive 
episodes associated with bipolar I or II disorder. 
Primary endpoint was change in Montgomery–Åsberg 
Depression Rating Scale (MADRS) total scores (baseline 
to week 8), and secondary endpoint was mean Clinical 
Global Impressions-Improvement score (week 8). 
Patients were randomized (N = 233) 1:1:1 to placebo, 
‘low-dose’ 0.25–0.5 mg/day or ‘high-dose’ 1.5–3.0 mg/
day cariprazine. Adverse events, laboratory results, 
vital signs, extrapyramidal symptoms, and suicide risk 
were monitored. Neither cariprazine group significantly 
separated from placebo in primary (mixed-effect 
model repeated measures MADRS least-squares mean 
differences: low-dose = −0.7, P = 0.7408; high-dose = 0.0, 
P = 0.9961) or secondary efficacy measures. No new safety 
signals with cariprazine were observed and common 
treatment-emergent adverse events (≥5% of cariprazine 
patients and twice the rate of placebo) included insomnia, 
akathisia, dry mouth, nausea, weight increased, diarrhea, 
restlessness, vomiting, musculoskeletal stiffness, 
migraine, and cough. Metabolic and weight changes were 
generally similar for cariprazine and placebo. Factors 
that may have affected the outcome of the trial were 
identified, which helped to inform the design and conduct 
of subsequent phase 2b/3 clinical trials of cariprazine in 
bipolar depression. Int Clin Psychopharmacol 35: 147–156 
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Introduction
Acute and chronic major depressive episodes, subsyn-
dromal depressive symptoms, and dysphoria with mixed 
features comprise the majority of time spent unwell for 
patients with bipolar I or bipolar II disorder (Kupka et 
al., 2007). Episodes of depression are associated with 
increased rates of complications, including disability, mor-
bidity, and suicide (Chen and Dilsaver, 1996; Bottlender 
et al., 2000). Despite being a highly debilitating condition 
associated with significant psychiatric and medical comor-
bidities (Baldessarini et al., 2010), depressive episodes 
associated with bipolar disorder are less understood than 
manic or hypomanic episodes and relatively few phar-
macologic agents with proven treatment efficacy exist 
for their treatment (Post, 2012, 2016; Yatham et al., 2018). 
Traditional antidepressants continue to be commonly 
used for the treatment of depressive episodes despite 
limited empirical evidence indicating their efficacy, and 
availability of evidence suggesting their use may induce 
a switch to hypomanic, manic, or mixed features episode 
when used long term or intensify disease severity by 
increasing mood cycle frequency (Pacchiarotti et al., 2013; 
McGirr et al., 2016).
Dopamine receptor modulators are efficacious as a class 
treatment of bipolar mania, but currently, only olanzap-
ine-fluoxetine combination (SYMBYAX, 2009), quet-
iapine (Seroquel, 2013), cariprazine (Vraylar, 2019), and 
lurasidone (LATUDA, 2017) have obtained regulatory 
approval as first-line treatment options for acute bipo-
lar depression. Unlike the other agents that show low or 
negligible affinity for D
3
 receptors (Graff-Guerrero et al., 
2009; Mizrahi et al., 2011), cariprazine exhibits preferen-
tial binding to D
3
 receptors (Kiss et al., 2010) and also has 
high affinity for serotonin 5-HT
1A
 receptors in preclini-
cal models (Blier et al., 1997). Presumably, through these 
interactions, cariprazine enhances cognition (Marder et 
al., 2016), mood, and measures of reward, and reduces 
anhedonia in patients with schizophrenia (Gross and 
Drescher, 2012; Nakajima et al., 2013; Papp et al., 2014). 
Cariprazine is FDA-approved for the treatment of adults 
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with schizophrenia as well as acute manic, acute mixed, 
or depressive episodes associated with bipolar I disor-
der and is under investigation for the treatment of major 
depressive disorder (MDD).
A clinical trial program systematically assessed the effi-
cacy of cariprazine in the treatment of depressive episodes 
associated with bipolar disorder. To date, three phase 2b/3 
trials (Durgam et al., 2016; Earley et al., 2019a,b) reported 
on the efficacy of cariprazine in treatment of bipolar I 
depression. This is the first study to evaluate the efficacy, 
safety, and tolerability of flexible-dose ranges of caripra-
zine in the treatment of depressive episodes in patients 
with either bipolar I or II disorder.
Methods
This phase 2 study (protocol MD-52) was conducted 
from June 2009 to June 2010 in 26 centers in the USA 
(NCT00852202). The Institutional Review Board at 
each study center approved the study protocol and 
amendments. All patients were recruited and screened 
in compliance with the International Conference on 
Harmonization Good Clinical Practice Guideline and the 
Declaration of Helsinki and provided written consent 
after receiving a complete study description and prior to 
any study participation.
Study design
This was a multicenter, randomized, double-blind, pla-
cebo-controlled, parallel-group study in adult patients 
with bipolar I or II depression, which assessed two flex-
ible dosages of cariprazine (‘low-dose’: 0.25–0.75 mg/day 
and ‘high-dose’: 1.5–3.0 mg/day) compared with placebo. 
The double-blind treatment period was 8 weeks, which 
was preceded by ≥1-week drug washout period and fol-
lowed by a 2-week safety follow-up (no study medica-
tion). Eligible patients were randomized 1:1:1 to placebo, 
low-dose, or high-dose cariprazine using an interactive 
voice/web response system that assigned randomization 
and treatment allocation codes matching codes on the 
blinded medication packages. Patients, investigators, and 
study site personnel were blinded to allocation and treat-
ment assignment; blinding was maintained throughout 
and until completion of the study.
All investigational products provided by the Sponsor 
were identical in appearance and packaging, with codes 
corresponding to treatment allocation; patients were 
instructed to take the investigational product once daily 
consistently in either the morning or evening. Patients in 
the low-dose cariprazine group received the 0.25 mg/day 
dose during weeks 1–4. Patients in the high-dose caripra-
zine group were titrated from 0.5 to 1.5 mg/day during the 
first week, and then continued 1.5 mg/day. After week 4, 
the dose was increased to the higher dose (0.75 mg/day for 
low-dose group or 3.0 mg/day for high-dose group) if the 
response determined to be inadequate [<40% improve-
ment from baseline in Montgomery–Åsberg Depression 
Rating Scale (MADRS) total score] (Montgomery and 
Åsberg, 1979). After week 4, a dose decrease was allowed 
up to week 6, but no dose adjustments were allowed dur-
ing the first four or final two weeks of the double-blind 
treatment period.
Patients
Adult outpatients (18–65 years of age) with a principal 
diagnosis of bipolar I or II disorder using the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM-IV-TR) (APA, 2000) criteria with-
out psychotic features and with a current major depres-
sive episode of ≥4 weeks and ≤12 months, <8 episodes of 
a mood disturbance (depression, mania, hypomania, or 
mixed state) in the previous 12 months, and having at least 
one verified manic, hypomanic, or mixed episode were 
included in the study. Enrollment criteria also included 
scores of ≥20 on the 17-item Hamilton Depression Rating 
Scale (HAMD
17
) (Hamilton, 1960), ≥2 on Item 1 of the 
24-item HAMD (HAMD
24
) rating scale, and ≤12 on the 
Young Mania Rating Scale (YMRS) (Young et al., 1978). A 
physical examination, clinical laboratory, and electrocardi-
ogram (ECG) with no significant clinical results (as judged 
by investigators) were also required. Additional inclusion/
exclusion criteria and permitted psychotropic medica-
tions are listed in Supplementary Table 1, Supplemental 
digital content 1, http://links.lww.com/ICP/A74.
Efficacy
Efficacy was assessed by the change from baseline to 
week 8 in MADRS total score (primary) and Clinical 
Global Impressions – Improvement (CGI-I) score (sec-
ondary). Additional efficacy parameters included changes 
from baseline to week 8 scores on the Clinical Global 




 scales, and rates of MADRS response 
(≥50% reduction from baseline in total score), MADRS 
remission (score ≤ 10), CGI-I response (score ≤ 2), and 
HAMD
17
 remission (total score ≤ 7) at week 8.
Safety
Safety assessments included adverse event reporting (at 
every visit), clinical laboratory evaluations (at screening 
and end of study), and ECGs (at screening, weeks 1, 4 
and 8). Safety assessments conducted at baseline and at 
each double-blind study visit included vital signs, mania 
(using YMRS) (Young et al., 1978), and extrapyramidal 
symptoms (EPS) [Barnes Akathisia Rating Scale (BARS) 
(Barnes, 1989), the Abnormal Involuntary Movement 
Scale, and the Simpson–Angus Scale (SAS) (Simpson 
and Angus, 1970)]. Suicide risk was monitored at every 
visit using the Columbia-Suicide Severity Rating Scale 
(Posner et al., 2011).
Data analyses
Efficacy analyses were performed on the intent-to-
treat population (patients who took at least one dose of 
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investigational product and had at least one postbase-
line MADRS assessment). MADRS total score changes 
from baseline to week 8 were analyzed by mixed-effects 
model for repeated measures (MMRMs) with treatment 
group, study center, visit, and treatment group-by-visit 
as covariates. Primary MADRS score comparison was 
between placebo and the average of the low- and high-
dose cariprazine groups. If positive, a pairwise comparison 
between placebo and each cariprazine group was to be 
tested; this is a process for controlling for multiple com-
parisons. Two sensitivity analyses, using last-observation 
carried forward (LOCF) and observed cases approach, 
were performed on the primary efficacy parameter. An 
analysis-of-covariance model with treatment group and 
study center as factors and baseline MADRS total score 
as a covariate were used for both sensitivity analyses.
Analyses of the secondary outcome and additional con-
tinuous variables were each conducted using an MMRM 
method that was similar to the primary comparison, using 
the respective baseline scores as covariates. Analyses of 
categorical variables (response and remission rates) were 
done using a logistic regression model with treatment 
group and the corresponding baseline score as explan-
atory variables. All statistical analyses were performed 
using version 9.1.3 of Statistical Analysis Software (SAS 
Institute; Cary, North Carolina, USA).
Safety analyses were based on the safety population (ran-
domized patients who took at least one dose of inves-
tigational product). For each safety parameter, the last 
assessment before the first dose of double-blind study 
medication was used as baseline; continuous variables 
were summarized by number of patients, mean, and SD, 
and categorical variables were summarized by number 
and percentage of patients.
Sample size
The sample size was determined by calculating that 75 
patients per arm would provide 85% power to detect a 
treatment difference of 3.8 points in the primary efficacy 
parameter between the placebo group and the average 
of the two cariprazine treatment groups at the two-sided, 
5% significance level, assuming a common SD of 8 for 
the primary efficacy parameter, a correlation coefficient 
of 0.5 for within-patient assessments, and a 30% patient 
drop-out rate.
Results
Patient disposition and demographics
Of 448 patients screened, 233 were randomized (Fig. 1). 
Of 227 patients in the safety population, 172 (75.8%) 
completed the study (placebo = 77.9%; low-dose caripra-








76 allocated to cariprazine 0·25-0·75 
mg/d
79 allocated to placebo 78 allocated to cariprazine 1·5-3·0 mg/d
12 discontinued the study
3 had adverse events
1 had insufficient response
2 had protocol violations
1 withdrew consent
5 were lost to follow-up
0 other





5 lost to follow-up
1 other
26 discontinued the study
7 had adverse events
2 had insufficient response
7 had protocol violations
2 withdrew consent
6 were lost to follow-up
2 other
75 included in the ITT population75 included in the ITT population 74 included in the ITT population
63 completed the study60 completed the study 49 completed the study
77 included in the safety population 75 included in the safety population 75 included in the safety population
3 were excluded
1 had adverse events
2 lost to follow-up
1 was excluded
1 lost to follow-up
2 were excluded
1 lost to follow-up
1 withdrew consent 
Fig. 1
CONSORT flow diagram for study patients.
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follow-up’ was among the most common reasons for dis-
continuation in each treatment group, along with adverse 
events and protocol violations in the high-dose caripra-
zine group. Baseline demographics, clinical history, and 
baseline assessment scores were similar across treat-
ment groups (Table 1). The majority of patients (72.7%) 
were diagnosed with bipolar I disorder. Mean baseline 
MADRS and YMRS scores of ~30.5 and ~6.1, respec-
tively, suggested the patient population was moderately 
depressed on average, with low levels of mania (Snaith et 
al., 1986; Berk et al., 2008).
Efficacy
Primary efficacy parameter
MADRS scores were not significantly improved from 
baseline to week 8 compared with placebo for the average 
of the combined low- and high-dose cariprazine groups 
[least-squares mean difference (LSMD) = −0.3, 95% con-
fidence interval (CI) = −3.8, 3.2; P = 0.8522]. Similarly, the 
improvement in MADRS total scores from baseline to 
week 8 was not appreciably different relative to placebo 
in low-dose cariprazine (LSMD = −0.7, 95% CI = −4.6, 3.3; 
P = 0.7408) or high-dose cariprazine groups (LSMD = 0.0, 
95% CI = −4.1, 4.1, P = 0.9961) (Fig. 2).
Secondary and additional efficacy parameters
No significant difference between groups was observed 
in mean CGI-I scores at week 8, with a mean score of 
2.1 points for all treatment groups. Additional efficacy 
parameters were also similar across treatment groups, 
with no significant differences between groups (Table 2).
Exploratory analysis of efficacy
To evaluate the influence of placebo response on the 
results, a band-pass filter analysis was conducted, which 
excluded patient data from study centers with >50% 
MADRS response rates in the placebo group. The 
band-pass filter analysis used MMRM with an unstruc-
tured covariance matrix using treatment group, pooled 
center, visit, and treatment group-by-visit interaction 
as factors, and baseline plus baseline-by-visit interac-
tion as covariates. The data at week 6 were chosen for 
analysis as it has been suggested that treatment effect 
vs. placebo may be greater at 4–6 weeks than at week 
8. In the band-pass analysis, significant differences vs. 
placebo were observed for both the low-dose caripra-
zine (LSMD = −5.0, 95% CI = −9.61, −0.48; P < 0.05) 
and high-dose cariprazine groups (LSMD = −5.2, 95% 
CI = −9.81, −0.52, P < 0.05) (Supplementary Fig. 1, 




Median duration of treatment was similar across treat-
ment groups (55–56 days) with a mean (SD) mg/day dose 
of 0.35 (0.12) and 1.52 (0.42) in the low-dose and high-
dose cariprazine groups, respectively. Dose increases 
were administered in 38% of placebo, 45% of low-dose 
cariprazine, and 31% of high-dose cariprazine groups.
Adverse events
Overall treatment-emergent adverse events (TEAEs) 
were reported in similar percentages across all treatment 
groups (Table  3); however, adverse events leading to 
treatment discontinuation occurred more frequently in 
the high-dose group (9.3%) than in the placebo (2.6%) 
or low-dose cariprazine group (4.0%). Two patients each 
prematurely discontinued from the study due to suicidal 
ideation (high-dose cariprazine group), mania (low-dose 
cariprazine group), bipolar I disorder (high-dose caripra-
zine group), and depression (placebo and high-dose 
cariprazine groups). No premature discontinuations were 
due to EPS-associated TEAEs.
Table 1 Patient characteristics at baseline in the safety population
Cariprazine groups
Placebo group (N = 77) 0.25–0.75 mg/day (N = 75) 1.5–3.0 mg/day (N = 75)
Demographic characteristics
Age, years, mean (SD) 40.6 (10.7) 37.4 (10.7) 38.9 (11.2)
Female, n (%) 46 (59.7) 48 (64.0) 51 (68.0)
Race, n (%)
 Caucasian 54 (70.1) 56 (74.7) 62 (82.7)
 Non-Caucasian 23 (29.9) 19 (25.3) 13 (17.3)
Bipolar disorder history
Bipolar I, n (%); Bipolar II, n (%) 53 (68.8); 24 (31.2) 57 (76.0); 18 (24.0) 55 (73.3); 20 (26.7)
Number of depressive episodes, mean (SD) 17.4 (19.9) 14.8 (14.4) 16.1 (18.5)
Number of hypomanic, manic and mixed episodes, mean (SD) 16.6 (21.7) 10.7 (11.8) 16.2 (22.5)
Duration of bipolar disorder, years, mean (SD) 16.0 (10.3) 15.5 (9.7) 17.7 (10.5)
Duration of current depressive episode, months, mean (SD) 4.4 (3.1) 4.0 (3.0) 7.3 (26.0)
Baseline Rating Scale Scores, mean, SD
MADRS 30.0 (5.0) 30.2 (5.0) 31.0 (4.6)
YMRS 6.1 (3.2) 6.1 (3.4) 6.0 (3.4)
MADRS, Montgomery–Åsberg Depression Rating Scale; N, number of patients in the Safety Population; n, number of patients in category; YMRS, Young Mania Rating 
Scale.
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Common TEAEs among both cariprazine groups occur-
ring in ≥5% of patients and at least twice the rate of pla-
cebo included insomnia, akathisia, dry mouth, nausea, 
weight increased, diarrhea, restlessness, vomiting, mus-
culoskeletal stiffness, migraine, and cough. Akathisia 
was reported in 17% of high-dose cariprazine, 3% of 
low-dose cariprazine, and 4% of placebo groups. TEAEs 
considered related to treatment occurred in 53, 55, and 
69% of patients in the placebo, the low-, and high-dose 
cariprazine groups, respectively. Most adverse events 
were judged to be mild to moderate in intensity. Serious 
adverse events related to treatment occurred in six 
patients during the double-blind treatment period and 
were bipolar disorder and suicidal ideation (placebo), 
suicide attempt and spontaneous abortion (low-dose 
cariprazine), and bipolar I disorder and suicidal ideation 
(high-dose cariprazine). One death, a suicide in the pla-
cebo group, occurred 20 days after being lost to follow-up 
but was considered unrelated to treatment. Suicidal ide-
ation (of the lowest severity classification) was reported 
by ~20% of patients in each cariprazine group and 12% of 
patients in the placebo group, and suicidal behavior was 
reported in one patient in the low-dose cariprazine group.
Treatment-emergent mania
Mean decrease in YMRS scores was similar across treat-
ment groups with a score change of −2.1, −1.3, and −1.9 
for placebo, low-dose cariprazine, and high-dose caripra-
zine, respectively. Treatment-emergent mania (postbase-
line YMRS total score ≥ 16) was reported in 10, 8, and 15% 
of patients in the placebo, low-dose cariprazine, and high-
dose cariprazine groups, respectively.
Clinical parameters
Changes in clinical laboratory values, vital signs, and 
ECGs were unremarkable, with a low incidence of poten-
tially clinically significant values across treatment groups 
(Table 4). Changes in clinical laboratory values and vital 
sign parameters were similar across treatment groups 
(Supplementary Table 2, Supplemental digital content 
1, http://links.lww.com/ICP/A74); however, changes in ala-
nine aminotransferase and prolactin values were slightly 
higher in both cariprazine groups compared with placebo 
group. Mean (SD) kg weight changes were +0.30 (2.16), 
+0.62 (2.76), and +1.42 (2.93) in the placebo, low-dose 
cariprazine and high-dose cariprazine groups, respec-
tively. Weight increases ≥7% of  body weight occurred 
in 5% of the low-dose cariprazine and 7% of high-dose 
cariprazine groups.
Discussion
This exploratory phase 2 trial in patients with bipolar I 
or bipolar II depression failed to detect statistically sig-
nificant differences between cariprazine and placebo on 
any prospectively defined efficacy outcomes. The results 
of this study are discordant with results from other tri-
als evaluating dopamine receptor modulators, including 
quetiapine (Calabrese et al., 2005; Thase et al., 2006), lur-
asidone (Loebel et al., 2014), and olanzapine (Tohen et al., 
2012), which all demonstrated efficacy for the treatment 
Fig. 2
Mean change from baseline in MADRS total score (MMRM, ITT population). ITT, intent to treat; MADRS, Montgomery–Åsberg Depression Rating 
Scale; MMRM, mixed-effects model for repeated measures.
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of bipolar depression. Learnings from the present trial, as 
discussed below, were used to design three subsequent 
phase 2b/3 randomized controlled trials of cariprazine 
for the treatment of bipolar I depression, which success-
fully demonstrated improvement in depressive symp-
toms with both 1.5 and 3.0 mg/day cariprazine vs. placebo 
(Durgam et al., 2016; Earley et al., 2019a,b).
In the present trial, a high rate of placebo response was 
a major confounding factor. Although all four trials had 
comparable mean baseline MADRS scores (30.0–31.3), 
the average change from baseline in MADRS total score 
for placebo patients in the present trial was approxi-
mately −16 at week 6 (Fig. 2), while it was much smaller 
for placebo groups in subsequent positive studies (−11.1 
to −12.9) (Durgam et al., 2016; Earley et al., 2019a,b).
The exploratory post-hoc band-pass analysis supports 
greater efficacy at week 6 and indicates that a high pla-
cebo response at some clinical sites may have impaired 
the ability to detect treatment differences in the total 
population. Flexible dosing may also have reduced the 
ability to see differences at later time points. Given the 
option to increase to a higher dose (including the pla-
cebo group, because all patients and investigators were 
blinded), patients on placebo who did not respond ini-
tially may have been given a higher ‘dose’ later. This 
could increase the chances of a placebo effect, whereby 
they report a perceived improvement in symptoms 
despite only receiving placebo. Even with fixed-dosing, 
patients who receive placebo may tend to report progres-
sive symptom improvement over time. Evidence of this 
Table 2 Secondary and additional efficacy outcomes at week 8 in the (ITT) population
Placebo group (n = 75)
Cariprazine groups
Cariprazine average – placeboa0.25–0.75 mg/day (n = 75) 1.5–3.0 mg/day (n = 74)
Primary efficacy parameter: MADRS total score change at week 8, MMRM
 Baseline mean ± SEM 29.9 ± 0.6 30.2 ± 0.6 30.9 ± 0.5 –
 Change mean ± SEM −16.6 ± 1.5 −16.8 ± 1.3 −16.1 ± 1.6 –
 LSMD vs. placebo (95% CI) – −0.7 (−4.6, 3.3) 0.0 (−4.1, 4.1) −0.3 (−3.8, 3.2)
 P valueb – 0.7408 0.9961 0.8522
Secondary efficacy parameter: CGI-I score at week 8, MMRM
 Mean ± SEM 2.1 ± 0.1 2.1 ± 0.1 2.1 ± 0.2 –
 LSMD vs. placebo (95% CI) – −0.1 (−0.6, 0.3) −0.2 (−0.6, 0.3) –
 P valueb – 0.5681 0.4539 –
Additional efficacy parameters
 CGI-S score change at week 8, MMRM
  Baseline, mean ± SEM 4.3 ± 0.1 4.4 ± 0.1 4.4 ± 0.1 –
  Change at week 8, mean ± SEM −1.8 ± 0.2 −1.7 ± 0.2 −1.8 ± 0.2 –
  LSMD vs. placebo (95% CI) – 0.0 (−0.4, 0.5) −0.1 (−0.5, 0.4) −0.0 (−0.4, 0.4)
  P valueb – 0.9167 0.7138 0.8773
 HAMD
24
 total score change at week 8, MMRM
  Baseline, mean ± SEM 29.4 ± 0.5 30.2 ± 0.5 30.0 ± 0.5 –
  Change at week 8, mean ± SEM −16.5 ± 1.4 −17.0 ± 1.2 −16.6 ± 1.3 –
  LSMD vs. placebo (95% CI) – −0.5 (−4.1, 3.0) −0.2 (−3.8, 3.4) −0.4 (−3.5, 2.7)
  P valueb – 0.7642 0.9201 0.8178
 HAMD
17
 total score change at week 8, MMRM
  Baseline, mean ± SEM 23.3 ± 0.3 23.8 ± 0.4 23.8 ± 0.3 –
  Change at week 8, mean ± SEM −13.0 ± 1.1 −13.0 ± 0.9 −12.7 ± 1.1 –
  LSMD vs. placebo (95% CI) – −0.2 (−2.9, 2.5) 0.2 (−2.6, 3.0) 0.0 (−2.4, 2.4)
  P value – 0.8936 0.8891 0.9962
 MADRS response (≥50% reduction from baseline at week 8), LOCF
  Responders, n/N1 (%)c 37/75 (49.3) 42/75 (56.0) 40/74 (54.1) –
  Odds ratio vs. placebo (95% CI) – 1.32 (0.69, 2.51) 1.25 (0.65, 2.38) –
  P valuec – 0.4026 0.5066 –
 MADRS remission (MADRS total score ≤10 at week 8), LOCF
  Remitters, n/N1 (%)c 29/75 (38.7) 36/75 (48.0) 32/74 (43.2) –
  Odds ratio vs. placebo (95% CI) – 1.50 (0.78, 2.88) 1.29 (0.66, 2.51) –
  P valuec – 0.2298 0.4512  
 CGI-I response (CGI-I score ≤2 at week 8), LOCF
  Responders, n/N1 (%)c 41/57 (54.7) 48/75 (64.0) 42/74 (56.8) –
  Odds ratio vs. placebo (95% CI) – 1.53 (0.79, 2.96) 1.12 (0.58, 2.14) –





 total score ≤7 at week 8), LOCF
  Responders, n/N1 (%)d 28/75 (37.3) 30/75 (40.0) 28/74 (37.8) –
  Odds ratio vs. placebo (95% CI) – 1.16 (0.60, 2.24) 1.06 (0.54, 2.06) –
  P valuec – 0.6681 0.8710 –
CGI-I, Clinical Global Impressions – Improvement; CGI-S, Clinical Global Impression-Severity; CI, confidence interval; HAMD, Hamilton Depression Rating Scale, ITT, 
Intent-to-treat; LOCF, last observation carried forward; LSMD, least squares mean difference; MADRS, Montgomery–Åsberg Depression Rating Scale; MMRM, mixed-ef-
fects model for repeated measures.
aP values are based upon a comparison of the average effect of cariprazine 0.25–0.75 mg/day and cariprazine 1.5–3.0 mg/day with that of placebo.
bP values are from an MMRM model with treatment group, pooled study center, visit, and treatment group-by-visit interaction as factors, and baseline value and baseline-
by-visit interaction as the covariates.
cP values were based on a logistic regression model with treatment group and corresponding baseline scores as explanatory variables.
dn, number of patients in category; N1, number of patients available for analysis at a specific time point in the ITT population.
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was seen in a subsequent fixed-dose trial where symptom 
improvement began to plateau around 4–6 weeks in the 
active treatment groups but continued to decline in the 
placebo group (Durgam et al., 2016).
In retrospect, the study probably did not have sufficient 
power to detect efficacy given the smaller sample size; 
the anticipated difference of 3.8 points was overly opti-
mistic, and a more realistic estimate would have been 
lower. In the subsequent studies of cariprazine in bipo-
lar depression, the average difference was ~2.7 points 
for the 1.5 and 3 mg groups combined (Saraf et al., 2019). 
Moreover, the current study included an ineffective 
low-dose (0.25–0.75 mg) group, which further reduced 
the expected treatment effect and power. Additionally, 
approximately one-quarter of the patients in the study 
population had a bipolar II disorder diagnosis, which 
may have increased variability and impaired the ability 
to detect a treatment effect. Nevertheless, this study 
provided useful information that was used to improve 
the design and success of subsequent studies of caripra-
zine. While the primary efficacy analysis did not observe 
an effect for low-dose cariprazine (0.25–0.75 mg), it did 
show that high-dose cariprazine (1.5–3.0 mg) had a sig-
nal. Subsequent studies used 1.5 or 3.0 mg fixed-doses 
Table 3 Summary of adverse events in the safety population
Adverse event summary Placebo group (N = 77)
Cariprazine groups
0.25–0.75 mg/day (N = 75) 1.5–3.0 mg/day (N = 75)
Deaths, n 1a 0 0
Patients with any TEAEs, n (%) 61 (79.2) 59 (78.7) 60 (80.0)
Serious adverse events, n (%) 2 (2.6) 2 (2.7) 2 (2.7)
AEs leading to discontinuation, n (%) 2 (2.6) 3 (4.0) 7 (9.3)
Common adverse events (≥5% in any treatment group in the double-blind treatment period), n (%)
 Insomnia 7 (9) 13 (17) 15 (20)
 Akathisia 3 (4) 2 (3) 13 (17)
 Headache 10 (13) 11 (15) 12 (16)
 Dry mouth 4 (5) 6 (8) 10 (13)
 Nausea 3 (4) 9 (12) 9 (12)
 Upper respiratory tract infection 8 (10) 8 (11) 8 (11)
 Nasopharyngitis 5 (7) 6 (8) 7 (9)
 Fatigue 5 (7) 6 (8) 6 (8)
 Weight increased 1 (1) 1 (1) 6 (8)
 Diarrhea 5 (7) 10 (13) 5 (7)
 Anxiety 5 (7) 2 (3) 5 (7)
 Restlessness 2 (3) 2 (3) 5 (7)
 Vomiting 1 (1) 1 (1) 5 (7)
 Musculoskeletal stiffness 0 0 4 (5)
 Constipation 4 (5) 5 (7) 3 (4)
 Migraine 1 (1) 5 (7) 0
 Cough 1 (1) 4 (5) 0
N, number of patients in the safety population; n, number of patients with treatment-emergent adverse events; TEAE, treatment-emergent adverse events.
aOne patient died within 30 days of the last dose of study medication. This patient was entered into the study twice (at different study sites). She first received cariprazine 
1.5–3.0 mg/day for 57 days and completed the study. During the last week of participation at the first study site, the patient entered the study again at different sites and 
received double-blind placebo for 14 days and was lost to follow-up; it was learned that the patient committed suicide 20 days after the last dose of study medication. 
The death was not considered related to treatment.
Table 4 Potentially clinically significant postbaseline laboratory values in the safety population during the double-blind treatment period
Parameter, Unit PCS criteria (Unit) Placebo (N = 77), n/N1 (%)a
Cariprazine groups
0.25–0.75 mg/day (N = 75), 
n/N1 (%)a 
1.5–3.0 mg/day (N = 75), 
n/N1 (%)a 
Cholesterol LDL ≥1.2 × ULN (mmol/L) 5/55 (9.1) 3/50 (6.0) 1/53 (1.9)
Total >1.3 × ULN (mmol/L) 6/64 (9.4) 3/59 (5.1) 1/60 (1.7)
CPK >1.5 × ULN (U/L) 5/65 (7.7) 1/58 (1.7) 1/58 (1.7)
Glucose, fasting <0.8 × LLN (mmol/L) 0/58 0/56 1/55 (1.8)
>1.2 × ULN (mmol/L) 0/58 2/56 (3.6) 0/55
Triglycerides >1.2 × ULN (mmol/L) 1/58 (1.7) 2/52 (3.8) 6/61 (9.8)
Albumin >1.1 × ULN (g/L) 0/70 1/64 (1.6) 0/65
Blood urea nitrogen >1.2 × ULN (mmol/L) 1/70 (1.4) 0/64 0/65
Uric acid (urate) >1.1 × ULN (µmol/L) 2/70 (2.9) 0/63 0/63
No patients had PCS albumin, alkaline phosphatase, ALT, AST, calcium, chloride, total bilirubin, HDL, creatinine, potassium, protein, sodium, eosinophil, hemoglobin, 
neutrophil, or platelet values.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; LDL, low density lipoprotein; LLN, lower limit of normal;.N, number of 
patients in the safety population; PCS, potentially clinically significant; ULN, upper limit of normal. 
aPercentages are calculated as (n/N1) × 100 (n = number of patients who had a non-PCS baseline value and at least one PCS postbaseline value; N1 = number of 
patients with a non-PCS value and at least one postbaseline assessment).
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were restricted to bipolar I disorder, and were powered 
with twice as many patients randomized to double-blind 
treatment.
A high proportion of failures in clinical trials of treat-
ments for depressive symptoms in patients with acute 
bipolar depression and MDD have presumably resulted 
from higher than expected rates of placebo response and 
is recognized as a major impediment to the clinical devel-
opment of new medications (Khan et al., 2003; Yatham 
et al., 2016). Various analyses have shown that antide-
pressant monotherapy trials with placebo response rates 
higher than 30% have a low probability of demonstrat-
ing statistically significant efficacy for active compounds 
over placebo ( Khan et al., 2003; Iovieno and Papakostas, 
2012). A post-hoc band-pass filter analysis of the data 
from this study suggested that both low- and high-dose 
cariprazine were effective in treating depression if all the 
data from centers that had >50% placebo response were 
excluded, confirming that higher placebo response was 
a major contributor to the failure of this study to detect 
a significant treatment effect. Strategies for addressing 
high placebo response rates and improving the ability 
to detect meaningful differences between active com-
pounds and placebo in clinical trials include reducing the 
number of trial sites, keeping the number of capsules the 
same even with the dose increase, reducing the duration 
of the double-blind phase, and developing novel study 
designs and analyses (Khan et al., 2004).
Learnings in the present study, which were applied to 
subsequent phase 2b/3 trials in the program, included 
employing a more gradual titration methodology, to 
potentially lower rates of akathisia and discontinu-
ations due to adverse events, assessment of higher 
doses of cariprazine, and inclusion of only patients with 
bipolar type I disorder. In this study, aggressive dose 
escalation may have had a negative impact on efficacy 
and tolerability outcomes, particularly in the high-dose 
cariprazine patients who experienced high levels of dis-
continuation due to adverse events. Rates of discontin-
uations in the high-dose cariprazine group were higher 
than comparable dose groups in other cariprazine bipo-
lar depression trials (Durgam et al., 2016; Earley et al., 
2019a,b). Also, increasing attrition over time may partly 
explain why the initial numerical separation between 
high-dose cariprazine and placebo was not maintained. 
This trend was also observed in two failed aripiprazole 
bipolar depression studies (Thase et al., 2008), which 
also had an aggressive titration methodology, high rates 
of attrition (~41–47%), and initial separation from pla-
cebo (from baseline to week 6) that was not maintained 
at trial endpoint (week 8) (Thase et al., 2008; Post, 
2016).
Additionally, the phase 3 trials in the cariprazine program 
reported rates of akathisia of less than 10% (Earley et al., 
2019a,b), compared to 17% in this study. High akathisia 
rates may have negatively affected efficacy outcomes, 
as its symptoms may be experienced by the patient and 
interpreted by the clinician as a worsening of the underly-
ing depression. The titration methodology was modified 
in the phase 3 trials to only allow dose escalations to the 
highest dose (3.0 mg/day) after two weeks of treatment 
at 1.5 mg/day. Furthermore, the present study may have 
selected a cariprazine dose too low to effectively treat 
depressive symptoms, partially explaining the lack of 
significant improvement in the low-dose (0.25–0.75 mg/
day) group. The mean daily dose of cariprazine for the 
group was only 0.35 mg/day, and significant improve-
ment in depressive symptoms has not been previously 
reported with daily dose less than 1.5 mg/day (Durgam et 
al., 2016). This learning was applied to the phase 3 pro-
gram by assessing a minimum cariprazine dose of 1.5 mg/
day (Earley et al., 2019a,b).
Cariprazine was generally well tolerated in this study, 
and TEAEs occurred with similar frequency across 
treatment groups. As would be expected for a dopamine 
receptor modulator, the incidence of akathisia (both 
as a reported adverse event and as measured by the 
BARS) was highest among patients treated with high-
dose cariprazine (1.5–3.0 mg/day) and the rates may be 
partially explained by the titration methodology used, 
as previously discussed. Other than akathisia, the inci-
dence of EPS events was low and comparable to placebo 
in both cariprazine dose groups. The incidence of som-
nolence and sedation, which were significantly higher for 
dopamine receptor modulators vs. placebo analyzed in a 
meta-analysis (De Fruyt et al., 2012), were low among all 
treatment groups in this study. Mean weight gain was 
highest in the high-dose cariprazine patients, but no 
treatment groups exceeded 1.5 kg. Weight gain exceed-
ing 7% of body weight was more frequently reported 
among patients in the high-dose cariprazine group than 
other groups, with an overall incidence of approximately 
7%. Metabolic parameter shifts into abnormal ranges 
were minimal and not considered to be clinically rele-
vant. The reasonable benefit–risk ratio of cariprazine in 
regards to weight gain and metabolic findings is impor-
tant because patients with bipolar disorder and those 
treated with dopamine receptor modulators often expe-
rience an increased risk of cardiovascular disease, meta-
bolic disorders, diabetes, and clinical obesity (Correll et 
al., 2008), and because incidences of these complications 
can lead to decreased medication adherence (Kemp, 
2014).
Limitations
Limitations of this study included the lack of an active 
comparator to establish assay sensitivity and exclusion 
of patients with significant medical and psychiatric con-
ditions, including suicidality, which is prevalent in this 
population (APA, 2002; Valtonen et al., 2006), limiting the 
generalizability of these findings. Although more aligned 
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with clinical practice, the fixed-flexible dose design pre-
vented assessment of specific cariprazine doses.
Conclusion
Although cariprazine did not significantly separate from 
placebo in this bipolar depression trial, factors that may 
have affected the outcome of the trial were identified. 
These factors helped to inform the design and conduct of 
subsequent phase 2b/3 clinical trials, which found signif-
icant improvements in depressive symptoms in patients 
with bipolar I disorder and a current depressive episode. 
Efforts to understand the causes of placebo response 
and minimize its occurrence in bipolar depression treat-
ment trials will improve research efforts and support the 
development of the new treatments that are needed for 
bipolar depression. Both cariprazine doses did not affect 
metabolic parameters and weight changes to a clinically 
significant degree and had favorable tolerability profiles.
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